Detalhe da pesquisa
1.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 384(8): 705-716, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626253
2.
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
Eur J Haematol
; 111(5): 815-823, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37574220
3.
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
Br J Haematol
; 198(1): 93-102, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383886
4.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Blood
; 136(22): 2513-2523, 2020 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32735641
5.
Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains.
Eur J Haematol
; 108(3): 204-211, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34767270
6.
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Br J Haematol
; 193(3): 532-541, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33559897
7.
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Br J Haematol
; 194(3): 496-507, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724461
8.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
9.
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Eur J Haematol
; 107(4): 416-427, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34129703
10.
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Eur J Haematol
; 107(3): 333-342, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34053112
11.
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Eur J Haematol
; 106(5): 673-681, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539037
12.
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Am J Hematol
; 96(5): 552-560, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650179
13.
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Blood
; 132(24): 2546-2554, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30352784
14.
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Blood
; 131(8): 855-863, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203585
15.
Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.
Haematologica
; 105(12): 2813-2823, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33256380
16.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 375(14): 1319-1331, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27705267
17.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 373(7): 621-31, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26035255
18.
The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership.
Br J Haematol
; 196(5): e52-e54, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34741302
19.
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Br J Haematol
; 178(6): 896-905, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677826
20.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Blood
; 124(16): 2498-506, 2014 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25202139